Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial. (linkinghub.elsevier.com)

Authors: Wagner L … Messier M Journal: Lancet Infectious Diseases Published: 2026-03-01 DOI: https://doi.org/10.1016/S1473-3099(25)00541-9